首页> 外文期刊>Clinical microbiology and infection: European Society of Clinical Microbiology and Infectious Diseases >Failure to elicit seroresponses to pneumococcal surface proteins (pneumococcal histidine triad D, pneumococcal choline-binding protein A, and serine proteinase precursor A) in children with pneumococcal bacteraemia
【24h】

Failure to elicit seroresponses to pneumococcal surface proteins (pneumococcal histidine triad D, pneumococcal choline-binding protein A, and serine proteinase precursor A) in children with pneumococcal bacteraemia

机译:患有肺炎球菌菌血症的儿童未能引起对肺炎球菌表面蛋白(肺炎球菌组氨酸三联体D,肺炎球菌胆碱结合蛋白A和丝氨酸蛋白酶前体A)的血清反应

获取原文
获取原文并翻译 | 示例
           

摘要

Pneumococcal surface proteins (PSPs) elicit antibody responses in infants and young children exposed to Streptococcus pneumoniae. These seroresponses could contribute to the aetiological diagnosis of pneumococcal disease, e.g. during the clinical development of novel PSP-based vaccines. In this study, we assessed the kinetics of antibody responses to three highly conserved and immunogenic PSPs (pneumococcal histidine triad D (PhtD), pneumococcal choline-binding protein A (PcpA), and serine proteinase precursor A (PrtA)) in 106 children (median age, 21.3 months; males, 58.5%) admitted for pneumococcal bacteraemia. Anti-PhtD, anti-PcpA and anti-PrtA antibodies were measured by ELISA, and compared in 61 pairs of acute (≤7 days) and convalescent (>14 days of admission) serum samples. Acute serum titres were similar to those observed in healthy children, and were unaffected by the acid dissociation of circulating immune complexes. Despite proven bacteraemia, seroresponses (≥2-fold increase in anti-PSP antibody concentrations) were only identified in 31 of 61 children (50.8%), directed against PrtA (n=23, 37.7%), PcpA (n=19, 31.1%), and PhtD (n=16, 26.2%), or several PSPs (two PSPs, n=13, 21.3%; three PSPs, n=7, 11.5%). Certain seroresponses were very strong (maximal fold-increases: PhtD, 26; PcpA, 72; PrtA, 12). However, anti-PSP antibody concentrations failed to increase in the convalescent sera of 30 of 61 (49.2%) bacteraemic children, and even declined (≥2 fold) in 13 of 61 (21.3%), mostly infants aged <6 months (8/13, 61.5%), possibly through consumption of maternal antibodies. Thus, pneumococcal bacteraemia may fail to elicit antibody responses, and may even have an antibody-depleting effect in infants. This novel observation identifies an important limitation of serology-based studies for the identification of bacteraemic children.
机译:肺炎球菌表面蛋白(PSP)在暴露于肺炎链球菌的婴幼儿中引起抗体反应。这些血清反应可能有助于肺炎球菌疾病的病因学诊断,例如在基于PSP的新型疫苗的临床开发过程中。在这项研究中,我们评估了106名儿童中对三种高度保守且具有免疫原性的PSP(肺炎球菌组氨酸三联体D(PhtD),肺炎球菌胆碱结合蛋白A(PcpA)和丝氨酸蛋白酶前体A(PrtA))的抗体反应动力学。中位年龄21.3个月;男性58.5%)因肺炎球菌菌血症而入院。通过ELISA测量抗PhtD,抗PcpA和抗PrtA抗体,并在61对急性(≤7天)和恢复期(入院> 14天)血清样品中进行比较。急性血清滴度与健康儿童相似,不受循环免疫复合物酸解离的影响。尽管已证实存在菌血症,但仅在61名儿童中有31名(50.8%)识别出血清反应(抗PSP抗体浓度增加2倍以上),针对PrtA(n = 23,37.7%),PcpA(n = 19,31.1) %)和PhtD(n = 16,26.2%)或几个PSP(两个PSP,n = 13,21.3%;三个PSP,n = 7,11.5%)。某些血清反应非常强(最大倍增:PhtD,26; PcpA,72; PrtA,12)。然而,在61名细菌学儿童中有30名(49.2%)的康复儿童血清中抗PSP抗体的浓度没有增加,在61名细菌学儿童中有13名(21.3%)甚至下降(≥2倍),主要是年龄小于6个月的婴儿(8 / 13,61.5%),可能是由于消耗了母源抗体。因此,肺炎球菌菌血症可能无法引起抗体反应,甚至可能对婴儿产生抗体消耗效应。这项新颖的发现确定了基于血清学的研究对细菌性儿童鉴定的重要局限性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号